Intralesional Acyclovir Versus Intralesional Zinc Sulphate in the Treatment of Plantar Warts
This clinical trial aims to compare the efficacy and safety of intralesional acyclovir versus intralesional zinc sulphate in the treatment of plantar warts.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
Viral warts represent benign epidermal proliferations associated with human papillomavirus (HPV) infection. HPV is a double-stranded DNA virus with more than 150 identified types, several of which have a predilection for cutaneous tissues and can produce distinct clinical forms of warts. Transmission occurs through direct skin-to-skin contact, indirect contact with contaminated surfaces, or autoinoculation, as when a wart is scratched or picked and virus is carried to a new site.
Cutaneous warts occur worldwide, with an estimated overall population prevalence of roughly 10%, rising to 10-20% among school-aged children. Although warts may develop at any age, incidence climbs through childhood and peaks between 12 and 16 years. Most lesions are asymptomatic, but they are not without consequence: warts can produce cosmetic disfigurement and psychosocial distress, and those on weight-bearing surfaces such as the plantar skin can become painful with walking or pressure. The principal clinical types are common, plantar, plane, filiform, and genital warts.
Plantar warts, the focus of the present study, arise on the sole and are most commonly attributed to HPV types 1, 2, 4, 27 and 57. Because of the constant pressure exerted by weight-bearing, these lesions tend to grow inward rather than outward and are often covered by a thick overlying callus that can mask the lesion and delay diagnosis; adjacent warts may also coalesce into a mosaic pattern. Unlike many other cutaneous warts, plantar warts are frequently symptomatic, producing a sharp, well-localized pain on walking or standing that can meaningfully impair mobility and daily activities. Clinically, they are distinguished from corns and calluses by the presence of pinpoint black dots, corresponding to thrombosed dermal capillaries, and by interruption of the normal skin lines across the lesion.
Several therapeutic modalities are available for cutaneous warts, including destructive methods such as salicylic acid, cryotherapy, silver nitrate, electrosurgery and pulsed-dye laser, antiproliferative agents such as formaldehyde, vitamin D3, bleomycin, 5-fluorouracil, podophyllin and podophyllotoxin, topical immunological agents such as imiquimod ; However, treatment remains challenging because of variable efficacy, prolonged treatment courses, recurrence and adverse effects. No single treatment option is considered gold standard.
Intralesional therapies are an emerging and effective approach for treating recalcitrant warts. Several immunotherapeutic agents for warts including vitamin D3; tuberculin purified protein derivative (PPD); Candida antigen (Candida); the measles, mumps, rubella (MMR) vaccine, BCG, zinc sulphate and antivirals such as acyclovir have demonstrated variable complete response rates in randomized controlled trials. Unlike various other treatment options, immunotherapeutic approaches upregulate the immune system to recognize and destroy the lesions at both the target site and distant locations.
Acyclovir, a synthetic purine nucleoside analogue, is active against herpes simplex virus (HSV) and varicella-zoster virus (VZV) through a selective activation pathway: viral thymidine kinase first converts the drug to its monophosphate form, after which host-cell enzymes complete its conversion to the active triphosphate metabolite. This triphosphate form competitively blocks viral DNA polymerase and, once incorporated into the elongating viral DNA strand, halts further chain extension, thereby arresting viral DNA synthesis.
Acyclovir is considered an evolving treatment option for warts; however, its mechanism of action against HPV is not fully understood. In a recent randomized controlled trial, intralesional acyclovir (70 mg/ml) was injected at a dose of 0.1 ml using an insulin syringe into each of the largest three warts (total 0.3 ml per session), repeated every 2 weeks until complete clearance or for a maximum of five sessions, resulting in a complete response rate of 37.5%.
The therapeutic effect of zinc sulphate in warts is thought to reflect a combination of direct local cytotoxicity and immune stimulation. Following intralesional injection, it triggers a localized inflammatory cascade in which eosinophils arrive first, followed sequentially by lymphocytes and fibroblasts, which may help drive immune-mediated clearance of HPV-infected keratinocytes. Zinc also contributes to immune regulation by supporting leukocyte and natural killer cell function. However, the precise mechanism by which intralesional zinc sulphate promotes HPV clearance remains incompletely understood.
Zinc sulfate has been investigated as an effective intralesional immunotherapy treatment for warts. A recent randomized controlled study evaluated intralesional 2% zinc sulphate in patients with common, plantar, and plane warts. Zinc sulphate was prepared by dissolving 2 g in 100 ml sterile distilled water and autoclaving at 95°C for 20 minutes. A dose of 0.1 ml was injected into the largest wart until blanching or bleb formation, with treatment repeated for up to six sessions. Complete response was achieved in 68.6% of patients, while complete clearance of the target wart was observed in 74.3% of cases.
Although both agents have demonstrated promising efficacy in the treatment of cutaneous warts, so far, there is no direct comparative study evaluating intralesional acyclovir versus intralesional zinc sulphate. Therefore, the present study aims to provide a direct head to head comparison of the efficacy and safety of intralesional acyclovir versus intralesional zinc sulphate in the treatment of patients with plantar warts.
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Silvana S Shawky, Resident
- Número de teléfono: 01099029774
- Correo electrónico: Silvana.18313420@med.aun.edu.eg
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients aged 18-50 years of both sexes clinically diagnosed with multiple plantar warts.
Exclusion Criteria:
- Patients with wart types other than plantar warts (genital, common, and plane warts).
- Pregnant or lactating women.
- Immunocompromised patients.
- Individuals receiving systemic immunosuppressive or antiviral therapy.
- History of hypersensitivity to acyclovir or zinc compounds.
- Patients with current acute febrile illness or any bacterial infection.
- Receiving any treatment for warts within 1 month before the study.
- Concurrent other skin disorders.
- Patients with systemic diseases (liver or renal disease, bleeding disorders).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Comparador activo: Intralesional Acyclovir
This group will receive intralesional acyclovir |
Intralesional injection of acyclovir, prepared using 250 mg acyclovir vial diluted with 3.5 ml saline (yielding an acyclovir concentration of approximately 70 mg/ml), at a dose of (0.1- 0.3 ml) injected into the largest (target) wart under aseptic precautions using an insulin syringe. The injection will be repeated every 2 weeks until complete clearance of warts or for a maximum of five sessions. |
|
Comparador activo: Intralesional Zinc Sulphate
This group will receive intralesional zinc sulphate 2% |
Intralesional injection of 2% zinc sulphate prepared using 2 gm of zinc sulphate powder dissolved in 100 ml of sterile distilled water and autoclaved at 95°C for 20 minutes, at a dose of (0.1- 0.3 ml) in the base of the largest (target) wart . The wart is injected with the solution till blanching or bleb formation. Subcutaneous injections and acral parts such as fingers and toes will be avoided, as it may cause vascular necrosis. Injections will be repeated for all patients into the same lesion every 2 weeks until complete clearance of warts or for a maximum of five sessions. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Clinical Response of the Injected Warts
Periodo de tiempo: 8 weeks
|
Clinical response assessed by standardized digital photographs and dermoscopic evaluation. Response will be graded using scoring system : Score 0: neither clinical nor dermoscopic response. Score 1: clinical improvement without dermoscopic clearance. Score 2: clinical disappearance with dermoscopic evidence of residual wart tissue. Score 3: complete clinical and dermoscopic clearance with return of normal skin markings. |
8 weeks
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Dalia A Attallah, Professor, Dermatology Department Assiut University Hospital, Assiut, Egypt
- Director de estudio: Radwa M Bakr, Assistant Professor, Dermatology Department Assiut University Hospital, Assiut, Egypt
Publicaciones y enlaces útiles
Publicaciones Generales
- Barkat MT, Abdel-Aziz RTA, Mohamed MS. Evaluation of intralesional injection of bleomycin in the treatment of plantar warts: clinical and dermoscopic evaluation. Int J Dermatol. 2018 Dec;57(12):1533-1537. doi: 10.1111/ijd.14092. Epub 2018 Jun 15.
- Youssef EMK, Eissa MAA, Bakr RM. Intralesional Candida albicans antigen versus intralesional zinc sulfate in treatment of cutaneous warts. Arch Dermatol Res. 2023 Jul;315(5):1305-1314. doi: 10.1007/s00403-022-02499-w. Epub 2022 Dec 26.
- Mohamed EE, Tawfik KM, Mahmoud AM. The Clinical Effectiveness of Intralesional Injection of 2% Zinc Sulfate Solution in the Treatment of Common Warts. Scientifica (Cairo). 2016;2016:1082979. doi: 10.1155/2016/1082979. Epub 2016 Mar 31.
- Gharib K, Taha A, Elradi M. Intralesional acyclovir versus intralesional Hepatitis-B vaccine in treatment of resistant plantar warts: a randomized controlled trial. Arch Dermatol Res. 2024 Jun 1;316(6):325. doi: 10.1007/s00403-024-03001-4.
- Mullen SA, Myers EL, Brenner RL, Nguyen KT, Harper TA, Welsh D, Keffer S, Mueller J, Whitley MJ. Systematic Review of Intralesional Therapies for Cutaneous Warts. JID Innov. 2024 Jan 24;4(3):100264. doi: 10.1016/j.xjidi.2024.100264. eCollection 2024 May.
- Al Aboud AM, Nigam PK. Wart. 2023 Aug 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK431047/
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Procesos Patológicos
- Atributos de la enfermedad
- Infecciones
- Enfermedades virales
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Enfermedades de transmisión sexual
- Infecciones por virus de ADN
- Enfermedades de la piel
- Enfermedades De La Piel Infecciosas
- Infecciones por virus tumorales
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades de la piel y del tejido conectivo
- Infecciones por virus del papiloma
- Verrugas
- Enfermedades De La Piel Virales
Otros números de identificación del estudio
Otros números de identificación del estudio
- PlantarWarts-RCT-2026
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .